Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Wang, Li ^a,b   Chen, Hongmin ^a,b   Pourgholami, Mohammad H ^b,c   Beretov, Julia ^b,c   Hao, Jingli ^b,c   Chao, Hongtu ^a,b   Perkins, Alan C ^d   Kearsley, John H ^b,c   Li, Yong ^b,c  

^a Henan Cancer Hospital   (China)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CD31 ANTIGEN; DOCETAXEL; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C595; MUCIN 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TAXOID; TUMOR MARKER;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ASCITES; CANCER INHIBITION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANIMAL; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; HUMAN; IMMUNOLOGY; METABOLISM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; SURVIVAL; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ANIMALIA; MUS; MUS MUSCULUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ASCITES; CA-125 ANTIGEN; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, NUDE; MUCIN-1; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052573203     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024405     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Yap TA, Carden CP, Kaye SB, (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9: 167-181.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
4. Harries M, Kaye SB, (2001) Recent advances in the treatment of epithelial ovarian cancer. Exp Opin Investig Drugs 10: 1715-1724.
5. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC, (2001) The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91: 1973-1982.
6. Li Y, Cozzi PJ, Russell PJ, (2010) Promising tumor-associated antigens for future prostate cancer therapy. Med Res Rev 30: 67-101.
7. Hu XF, Yang E, Li J, Xing PX, (2006) MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma. Expert Rev Anticancer Ther 6: 1261-1271.
8. Wang L, Ma J, Liu F, Yu Q, Chu G, et al. (2007) Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 105: 695-699.
9. Van Elssen CH, Frings PW, Bot FJ, Van de Vijver KK, Huls MB, et al. (2010) Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 57: 597-606.
10. Carraway KL III, Funes M, Workman HC, Sweeney C, (2007) Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol 78: 1-22.
11. Hughes ODM, Denley H, Kunkler RB, Denton G, Price MR, et al. (2000) MUC1mucin expression in transitional cell carcinoma of the bladder. J Urol Pathol 12: 179-191.
12. Price MR, Pugh JA, Hudecz F, Griffiths W, Jacobs E, et al. (1990) C595-a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer 61: 681-686.
13. Gendler S, Taylor-Papadimitriou J, Duhig T, Rothbard J, Burchell J, (1988) A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem 263: 12820-12823.
14. Perkins AC, Symonds IM, Pimm MV, Price MR, Wastie ML, et al. (1993) Immunoscintigraphy of ovarian carcinoma using a monoclonal antibody (111In-NCRC48) defining a polymorphic epithelial mucin (PEM) epitope. Nucl Med Commun 14: 578-586.
15. Li Y, Rizvi SMA, Brown JM, Cozzi PJ, Qu CF, et al. (2004) Antigenic expression human metastatic prostate cancer cell lines and primary prostate cancer sections for in vitro multiple targeted alpha therapy 213Bi-conjugated. Int J Radiat Oncol Biol Phys 60: 896-908.
16. Qu CF, Li Y, Song YJ, Rizvi SMA, Raja C, et al. (2004) MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213Bi-C595 radioimmunoconjugate. Brit J Cancer 91: 2086-2093.
17. Song YJ, Qu CF, Rizvi SMA, Robertson G, Raja C, et al. (2006) Cyotoxicity of PAI2, C595 and Herceptin vectors labelled with alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters. Cancer Lett 234: 176-183.
18. Qu CF, Song YJ, Li Y, Rizvi SMA, Smith R, et al. (2005) In vitro and in vivo inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A-C595. Cancer Bio Ther 4: 848-853.
19. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, et al. (2003) A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 88: 130-135.
20. Harries M, Gore M, (2002) Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. Lancet Oncol 3: 537-545.
21. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, et al. (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96: 1682-1691.
22. Smith JA, Ngo H, Martin MC, Wolf JK, (2005) An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol 98: 141-145.
23. de Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, et al. (2006) Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev 32: 471-482.
24. Zamboni WC, Strychor S, Joseph E, Parise RA, Egorin MJ, et al. (2008) Tumor, tissue, and plasma pharmacokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bearing SKOV-3 human ovarian xenografts. Cancer Chemoth Pharm 62: 417-426.
25. De Souza R, Zahedi P, Moriyama EH, Allen CJ, Wilson BC, et al. (2010) Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer. Mol Cancer Ther 9: 1820-1830.
26. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New Engl J Med 354: 34-43.
27. Wang L, Chen HM, Liu FH, Madigan MC, Hao JL, et al. (2011) Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Lett 300: 122-133.
28. Pourgholami MH, Cai ZY, Lu Y, Wang L, Morris DL, (2006) Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 12: 1928-1935.
29. Perry MC, (2001) Chemotherapy source book Philadelphia Lippincott, Williams and Wilkins; 2001.
30. Gerdes J, Schwab U, Lemke H, Stein H, (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20.
31. Naora H, Montell DJ, (2005) Ovarian cancer metastasis: integrating insights from disparate model organisms. Nature Rev Cancer 5: 355-366.
32. Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, et al. (2011) Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother. 2011 Apr 2, PMID: 21461842.
33. Oei AL, Moreno M, Verheijen RH, Sweep FC, Thomas CM, et al. (2008) Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int J Cancer 123: 1848-1853.
34. Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, et al. (2008) Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 14: 3060-3069.
35. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, et al. (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58: 4055-4060.
36. Shimizu M, Imai M, (2008) Effect of the antibody immunotherapy by the anti-MUC1 monoclonal antibody to the oral squamous cell carcinoma in vitro. Biol Pharm Bull 31: 2288-2293.
37. Moreno M, Bontkes HJ, Scheper RJ, Kenemans P, Verheijen RH, et al. (2007) High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC). Cancer Lett 257: 47-55.
38. Thie H, Toleikis L, Li J, von Wasielewski R, Bastert G, et al. (2011) Rise and fall of an anti-MUC1 specific antibody. PLoS ONE 6: e15921.
39. Stordal B, Pavlakis N, Davey R, (2007) A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev 33: 688-703.
40. Mollinedo F, Gajate C, (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8: 413-450.
41. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, et al. (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883-887.
42. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T, (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19: 4054-4057.
43. Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, et al. (2006) Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 24: 45-51.
44. Mesiano S, Ferrara N, Jaffe RB, (1998) Role of vascular endothelial growth factor in ovarian cancer-inhibition of ascites formation by immunoneutralization. Am J Pathol 153: 1249-1256.
45. Nishida N, Yano H, Komai K, Nishida T, Kamura T, et al. (2004) Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101: 1364-1374.
46. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, et al. (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809.
47. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, et al. (1995) Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43.
48. Bouchard VJ, Rouleau M, Poirier GG, (2003) PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 31: 446-454.
49. Jang SH, Wientjes MG, Lu D, Au JL, (2003) Drug delivery and transport to solid tumors. Pharm Res 20: 1337-1350.